A New Investigative Treatment Option for Acute Myeloid Leukemia Produces Positive Results
source: pixabay.com

A New Investigative Treatment Option for Acute Myeloid Leukemia Produces Positive Results

A new study has uncovered that using a hypomethylating agent in combination with a BCL2 inhibitor called Venetoclax may be advantageous as a therapeutic option for individuals with acute myeloid…

Continue Reading A New Investigative Treatment Option for Acute Myeloid Leukemia Produces Positive Results

New Investigative Therapy for Myelofibrosis Patients with Severe Thrombocytopenia is Making Headway

CTI BioPharma has just announced that they are submitting a NDA for Pacritinib as a new option for myelofibrosis patients who are facing severe thrombocytopenia. The thrombocytopenia is a result…

Continue Reading New Investigative Therapy for Myelofibrosis Patients with Severe Thrombocytopenia is Making Headway
Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements
source: pixabay.com

Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements

  This year, thanks to COVID-19, many conferences have been held online. These play a crucial role in spreading data, facilitating conversations, and determining potential treatment options for patients with…

Continue Reading Dr. Naveen Pemmaraju Discusses Myelofibrosis, MPNs, and Therapeutic Advancements

Virtual Event September 10th for Myeloproliferative Neoplasm International Awareness Day

Myeloproliferative neoplasm (MPN) International Awareness Day is on September 10th. This year, there will be a live streaming event to help bring awareness to this condition, instead of an in-person…

Continue Reading Virtual Event September 10th for Myeloproliferative Neoplasm International Awareness Day

Huntsman Lab Research Team Discovers that Selinexor May Benefit Myelofibrosis Patients Who have No Other Curative Options

  Myelofibrosis (MF) comes under the heading of rare cancer. A recent article in Newswise, University of Utah, describes the disease as the failure of bone marrow to produce normal…

Continue Reading Huntsman Lab Research Team Discovers that Selinexor May Benefit Myelofibrosis Patients Who have No Other Curative Options
Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
qimono / Pixabay

Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study

According to a publication from Oncology Nurse Advisor, a study of 109 patients with myeloproliferative neoplasms (certain types of blood cancers) found that mortality rates for younger patients were similar…

Continue Reading Age at Myeloproliferative Neoplasm Diagnosis Has Little Impact on Mortality Risk Says New Study
Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says
Katzenfee50 / Pixabay

Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says

According to a story from Cure Today, a recent study has found that identifying mutations in patients with myeloproliferative neoplasms may be the key in predicting outcomes, such as disease…

Continue Reading Mutations are the Key to Predicting Outcomes in Myeloproliferative Neoplasms, Study Says
Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released
stevepb / Pixabay

Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released

The drug Jakavi (ruxolitinib) is being investigated as a possible treatment for polycythemia vera (PV) and myelofibrosis. Results from studies into this were presented by Novartis at the 23rd Congress of…

Continue Reading Results From Trials of Jakavi For Treating Polycythemia Vera and Myelofibrosis Have Been Released